Following the company’s Q2, 2024 interim results, Echelon analyst Stefan Quenneville still thinks there is money to be made on Antibe Therapeutics
Related Keywords
Dan Legault , Stefan Quenneville , , Echelon Capital Markets , Antibe Therapeutics , Antibe Therapeutics Stock Quote , Speculative Buy ,
comparemela.com © 2020. All Rights Reserved.